As childhood obesity rates surge globally, pharma giants test weight loss drugs on kids despite safety concerns over side effects and long-term health impacts.
The U.S. Food and Drug Administration has urged online vendors to stop selling unapproved semaglutide and tirzepatide drugs due to public health concerns.
As childhood obesity rates surge globally, pharma giants test weight loss drugs on kids despite safety concerns over side effects and long-term health impacts.
The U.S. Food and Drug Administration has urged online vendors to stop selling unapproved semaglutide and tirzepatide drugs due to public health concerns.